Travere Therapeutics Inc

CEO Eric Dube’s recent $15.46‑per‑share buy at Travere Therapeutics shows insider confidence amid a rally, hinting at future growth in rare‑disease biotech.

Travere insider buys signal confidence: Chief Legal Officer’s 10,000‑share purchase below market shows long‑term optimism amid upcoming earnings.

Reed’s $19.08 buy at Travere Therapeutics signals insider confidence despite recent selling, hinting at a potential upside driven by future pipeline milestones.

Explore how Travere Therapeutics’ insider sales and option purchases shape investor outlook—balancing short‑term liquidity with long‑term growth potential.

Explore Travere’s insider “sell‑to‑cover” moves: routine tax‑cover trades, minimal price impact, and a net‑buying trend hinting at leadership confidence.